ILMN — Illumina, Inc.

Summary of Illumina Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Q4 revenue reached $1.16 billion, up 5% year-over-year (4% on a constant currency basis). Excluding Greater China, revenue grew 7%.
• Clinical Consumables: Revenue grew 20% year-over-year (ex-China), driven by increased adoption of sequencing-based diagnostic tests.
• Gross Margin: Non-GAAP gross margin was 67%, down 40 basis points year-over-year, primarily due to tariffs.
• Operating Margin: Non-GAAP operating margin improved to 23.7%, up 400 basis points year-over-year.
• Earnings Per Share (EPS): Non-GAAP EPS was $1.35, a 42% increase year-over-year, exceeding guidance.
• Free Cash Flow: Generated $321 million in Q4, totaling $1.1 billion for the year.

2. Strategic Updates and Business Highlights

• Growth Strategy: Illumina's strategy focuses on three pillars: core sequencing, scaling multiomics, and expanding services/data/software capabilities.
• Acquisition of Somalogic: Completed acquisition for $350 million to enhance multiomics capabilities, expected to strengthen Illumina's position in the proteomics market.
• BioInsight Launch: Introduced BioInsight, which integrates sequencing, CRISPR tools, and AI to enhance drug discovery processes.
• NovaSeq X Performance: Strong demand for NovaSeq X instruments, with Q4 placements being the second highest since launch, indicating robust growth in clinical applications.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected total revenue of $4.5 billion to $4.6 billion, representing 4% to 6% growth, with organic growth of 2% to 4% (excluding China).
• Clinical Growth: Anticipated double-digit to mid-teens growth in clinical consumables, while research consumables are expected to decline mid to high single digits.
• Operating Margin: Projected operating margins of 23.3% to 23.5% for 2026, with EPS guidance of $5.00 to $5.20, including dilution from the Somalogic acquisition.

4. Bad News, Challenges, or Points of Concern

• Research Market Challenges: Continued uncertainty in the research funding environment, with expectations of mid to high single-digit declines in research consumables.
• China Market Risks: Sales in Greater China were down 55% due to export restrictions, with ongoing discussions about the ability to import instruments into the country.
• Competitive Pressures: Competitors are pushing for lower pricing per genome, which may impact Illumina's pricing strategy and market share.

5. Notable Q&A Insights

• Operating Margin Expectations: Analysts inquired about the assumptions behind operating margin guidance, with management indicating a commitment to long-term targets despite dilution from acquisitions.
• Clinical vs. Research Growth: Clarifications were provided on the expected growth rates for clinical versus research segments, with clinical expected to drive overall growth.
• BioInsight's Potential: Discussion on how BioInsight could monetize AI capabilities in drug discovery, with significant interest from pharma partners noted.
• Academic Market Dynamics: Management acknowledged the challenges in the academic market but expressed optimism about improving conditions with potential NIH funding increases.

Overall, Illumina's Q4 2025 results reflect a strong finish to the year with significant growth in clinical consumables and a positive outlook for 2026, despite challenges in the research market and geopolitical risks in China.